Sunday 18 March 2018

Dublin-based drug company spins out new firm to focus on pulmonary disorders and fibrotic conditions

Adrian Weckler

Adrian Weckler

A Dublin-based drug discovery and development company, DS Biopharma, has spun out a new firm to focus on pulmonary disorders and fibrotic conditions.

The spin-out firm, Afimmune, is to continue the clinical development of a new anti-fibrotic compound called DS102. Afimmune also has other compounds in pre-clinical development, according to the company.

“By spinning out DS102 into a new company, DS Biopharma can direct its full attention to developing products for inflammatory skin conditions,” said Dr John Climax, chief executive “Afimmune will focus on fibrotic conditions and pulmonary disorders.”

Dr Climax is one of Ireland’s best known drug development entrepreneurs, having built another company, Icon, into one of the world’s biggest contract medical research companies over two decades.

DS Biopharma, headquartered in Leopardstown, is a privately held drug development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. The company is currently developing drugs for dermatitis and inflammatory skin disorders.

Online Editors

Business Newsletter

Read the leading stories from the world of Business.

Also in Business